Iron chelation, quo vadis?
- 1 August 2007
- journal article
- review article
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 11 (4) , 419-423
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Iron chelators as therapeutic iron depletion agentsExpert Opinion on Therapeutic Patents, 2006
- Changes in the Epidemiology of Thalassemia in North America: A New Minority DiseasePediatrics, 2005
- Iron in Nonhemochromatotic Liver DisordersSeminars in Liver Disease, 2005
- Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload diseaseJournal of Laboratory and Clinical Medicine, 1998
- 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE, AN ORALLY ACTIVE CHELATOR FOR TREATMENT OF IRON OVERLOADThe Lancet, 1987
- Effective Iron Chelation following Oral Administration of an Isoniazid‐Pyridoxal HydrazoneBritish Journal of Haematology, 1979
- 2,3-DHB Ineffective in Treatment of Iron OverloadNew England Journal of Medicine, 1977
- Chelation Studies with 2,3‐Dihydroxybenzoic Acid in Patients with β‐Thalassaemia MajorBritish Journal of Haematology, 1976
- Reassessment of the Use of Desferrioxamine B in Iron OverloadNew England Journal of Medicine, 1976
- Transfusion Therapy in Cooley's Anemia: Growth and Health as Related to Long‐Range Hemoglobin Levels. A Progress ReportAnnals of the New York Academy of Sciences, 1964